ArticleJournal of public health management and practice : JPHMP
Assessing User Engagement With an Interactive Mapping Dashboard for Overdose Prevention Informed by Predictive Modeling in Rhode Island.
Article in Journal of public health management and practice : JPHMP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trajectories of neighborhood-level overdose risk predictions for prioritization of harm reduction services: Results from the PROVIDENT study.Drug and alcohol dependence · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
contextPredictive modeling can identify neighborhoods at elevated risk of future overdose death and may assist community organizations' decisions about harm reduction resource allocation. In Rhode Island, PROVIDENT is a research initiative and randomized community intervention trial that developed and validated a machine learning model that predicts future overdose at a census block group (CBG) level. The PROVIDENT model prioritizes the top 20th percentile of CBGs at highest risk of future overdose death over the subsequent 6-month period. In CBGs assigned to the trial intervention arm, these predictions are then displayed for partnering community organizations via an interactive mapping dashboard.
objectiveTo evaluate whether CBGs prioritized by the PROVIDENT model were associated with increased user engagement via an online dashboard for fatal overdose forecasting and resource planning.
designWe estimated prevalence ratios using modified Poisson regression models, adjusted for CBG-level characteristics that may confound the relationship between model predictions and dashboard engagement.
settingWe used CBG-level data in Rhode Island (N = 809) from November 2021 to July 2024.
interventionOur exposure of interest was whether each CBG was prioritized by the PROVIDENT model and shown as prioritized on the interactive mapping dashboard.
main outcome measureOur primary outcome was whether a dashboard user from any partnering community organization engaged (eg, clicked, interacted with dashboard elements, or completed assessment or planning surveys) with each CBG on the interactive mapping dashboard.
resultsAfter adjusting for previous model predictions and dashboard engagement, nonfatal overdose counts, and distribution of race and ethnicity, poverty, unemployment, and rent burden, dashboard users were 1.0 to 2.4 times as likely to engage with CBGs prioritized by the PROVIDENT model that were shown as prioritized on the dashboard as compared to CBGs that were prioritized by the PROVIDENT model that were blinded on the dashboard.
conclusionsInteractive mapping tools with predictive modeling may be useful to support community-based harm reduction organizations in the allocation of resources to neighborhoods predicted to be at high risk of future overdose death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.